Pharmaceutical News

RSS

Certain anti-nausea medications used after operation could increase risk for irregular heartbeat

Certain commonly prescribed anti-nausea medications given to patients during or after an operation could increase their risk of developing an irregular heartbeat, new research has found.

19 Jun 2015

Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Alexza Pharmaceuticals, Inc. today announced that it has updated and amended its ADASUVE (Staccato loxapine) commercial partnerships with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, the Commonwealth of Independent States and other countries in Europe.

19 Jun 2015

Experimental AIDS vaccine candidate stimulates immune system to block infection in animal model

New research led by scientists at The Scripps Research Institute, International AIDS Vaccine Initiative and The Rockefeller University shows that an experimental vaccine candidate can stimulate the immune system to block HIV infection in mice.

18 Jun 2015

Scientists reveal new combination method that efficiently destroys cancer cells

Scientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells.

18 Jun 2015

Value of Colorectal Cancer therapeutics market expected to increase $9.4 billion by 2020

Analysis from business intelligence provider GBI Research - Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - states that the Colorectal Cancer (CRC) treatment market value will increase at a moderate Compound Annual Growth Rate (CAGR) of 1.8%, from $8.3 billion in 2013 to $9.4 billion by 2020.

18 Jun 2015

Autoantibodies play major role in IPF patients with acute exacerbations

Patients with acute exacerbations of idiopathic pulmonary fibrosis responded well to therapies similar to those used to treat autoimmune diseases, according to findings published today in PLOS ONE. The study suggests that autoantibodies — implicated in many autoimmune diseases such as rheumatoid arthritis or lupus — also play an important role in patients with acute exacerbations of IPF, a devastating lung disease.

18 Jun 2015

Exploring potential alternatives to needle injections

Needle injections have been around since 1657 and remain a key delivery method for many drugs, including vaccines that have prevented countless illnesses. But for patients that require daily pricks or for people in remote locations, the syringe model has major drawbacks. An article in Chemical & Engineering News looks at potential alternatives, their successes and their roadblocks.

18 Jun 2015

Unsafe prescribing increases risk of life threatening asthma attacks

Last year’s National Review of Asthma Deaths highlighted prescribing errors in nearly half of asthma deaths in primary care (47%). Now new analysis from Asthma UK, based on data from over 500 UK GP practices, reveals evidence that over 22,000 people with asthma in the UK, including 2,000 children, have been prescribed medicines (long-acting reliever inhalers) in a way that is so unsafe they have a ‘black box warning’ in the USA due to the risk they pose to the lives of people with asthma.

18 Jun 2015

Legalisation of medical marijuana does not increase use among teenagers, shows study

A nationwide study analysing 24 years of data (1991 to 2014) from over one million American adolescents in the 48 contiguous states has found no evidence that legalising the use of marijuana for medical purposes leads to increased use among teenagers.

18 Jun 2015

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.

17 Jun 2015

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

17 Jun 2015

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.

17 Jun 2015

AMRI, PerkinElmer form strategic collaboration to accelerate drug discovery

As further evidence of Governor Andrew M. Cuomo's successful establishment of a dynamic and growing bio-pharma sector in Buffalo, New York, Albany Molecular Research Inc. and PerkinElmer, Inc. today announced the formation of a strategic collaboration in connection with the opening of AMRI's drug discovery center as part of the new Buffalo Medical Innovation and Commercialization Hub.

17 Jun 2015

Rapamycin drug reduces obesity, preserves lean body mass in older rats

Aging can cause many changes to the body, including obesity and a loss of lean mass. Now, a group of University of Florida Health researchers has discovered that an existing drug reduces body fat and appetite in older rats, which has intriguing implications for aging humans.

17 Jun 2015

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

New research looks at quickly expanding effort to equip law enforcement officers with naloxone

Opioid overdose is one of the leading causes of accidental death in the U.S. According to the Centers for Disease Control and Prevention, the epidemic accounts for some 25,000 deaths per year--or approximately 68 fatalities per day.

17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Researchers locate promising target for potential vaccine against malaria

Researchers from the Johns Hopkins Bloomberg School of Public Health have located a new - and likely more promising, they say - target for a potential vaccine against malaria, a mosquito-borne illness that kills as many as 750,000 people each year.

16 Jun 2015

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.

16 Jun 2015

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.

16 Jun 2015

Pharmaceutical News

Certain anti-nausea medications used after operation could increase risk for irregular heartbeat

Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Experimental AIDS vaccine candidate stimulates immune system to block infection in animal model

Scientists reveal new combination method that efficiently destroys cancer cells

Value of Colorectal Cancer therapeutics market expected to increase $9.4 billion by 2020

Autoantibodies play major role in IPF patients with acute exacerbations

Exploring potential alternatives to needle injections

Unsafe prescribing increases risk of life threatening asthma attacks

Legalisation of medical marijuana does not increase use among teenagers, shows study

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

FDA accepts BiondVax's IND for Multimeric-001 vaccine

AMRI, PerkinElmer form strategic collaboration to accelerate drug discovery

Rapamycin drug reduces obesity, preserves lean body mass in older rats

Atopix raises additional development capital to investigate OC459 for treatment of asthma

New research looks at quickly expanding effort to equip law enforcement officers with naloxone

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Researchers locate promising target for potential vaccine against malaria

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News